{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T06:42:08Z","timestamp":1777444928819,"version":"3.51.4"},"reference-count":22,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"24","content-domain":{"domain":["www.ahajournals.org"],"crossmark-restriction":true},"short-container-title":["Circulation"],"published-print":{"date-parts":[[2005,6,21]]},"abstract":"<jats:p>\n            <jats:bold>\n              <jats:italic>Background\u2014<\/jats:italic>\n            <\/jats:bold>\n            Tecadenoson is a potent selective A\n            <jats:sub>1<\/jats:sub>\n            -adenosine receptor agonist with a dose-dependent negative dromotropic effect on the AV node. Tecadenoson terminates induced paroxysmal supraventricular tachycardia (PSVT) without the clinically significant side effects caused by stimulation of other adenosine receptors. This trial was designed to determine a safe and effective tecadenoson bolus for termination of electrophysiologically induced PSVT.\n          <\/jats:p>\n          <jats:p>\n            <jats:bold>\n              <jats:italic>Methods and Results\u2014<\/jats:italic>\n            <\/jats:bold>\n            Patients with a history of symptomatic PSVT and inducible PSVT at the time of a clinically indicated electrophysiology study were randomized into a multicenter, double-blind, placebo-controlled trial. Five 2-dose tecadenoson bolus regimens were evaluated versus placebo (75\/150, 150\/300, 300\/600, 450\/900, 900 \u03bcg\/900 \u03bcg). The second bolus was administered only if PSVT persisted for 1 minute after the first bolus. Each tecadenoson regimen resulted in a significant therapeutic conversion rate compared with placebo (range, 50.0% to 90.3%, analysis of all patients dosed; n=181;\n            <jats:italic>P<\/jats:italic>\n            &lt;0.0005). Conversion by the first bolus was dose related (range: placebo, 3.3% to 86.7% for 900 \u03bcg\/900 \u03bcg). Time to conversion was dose dependent, with a median time of &lt;1 minute for the 3 highest dose regimens. Postconversion arrhythmias were transient, requiring no additional treatment in 4 regimens (including placebo). Transient second- and third-degree heart block occurred at higher doses (300\/600, 450\/900, 900 \u03bcg\/900 \u03bcg) and was supported with backup pacing when needed. No effect on blood pressure was observed. Ten patients with a history of asthma or chronic obstructive pulmonary disease tolerated tecadenoson without bronchospasm.\n          <\/jats:p>\n          <jats:p>\n            <jats:bold>\n              <jats:italic>Conclusions\u2014<\/jats:italic>\n            <\/jats:bold>\n            We identified an optimal tecadenoson regimen (300 \u03bcg\/600 \u03bcg) that effectively and rapidly converted 90% (28 of 31) of PSVT patients to normal sinus rhythm with no significant adverse effects.\n          <\/jats:p>","DOI":"10.1161\/circulationaha.104.510982","type":"journal-article","created":{"date-parts":[[2005,6,15]],"date-time":"2005-06-15T03:43:53Z","timestamp":1118807033000},"page":"3202-3208","update-policy":"https:\/\/doi.org\/10.1161\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":32,"title":["Trial to Evaluate the Management of Paroxysmal Supraventricular Tachycardia During an Electrophysiology Study With Tecadenoson"],"prefix":"10.1161","volume":"111","author":[{"given":"Kenneth A.","family":"Ellenbogen","sequence":"first","affiliation":[{"name":"From the Medical College of Virginia, Richmond (K.A.E.); Regional Cardiology Associates, Sacramento, Calif (G.O.); Care Group, LLC, Indianapolis, Ind (E.N.P.); St George\u2019s Hospital Medical School, London, UK (J.A.C); and CV Therapeutics, Palo Alto, Calif (L.M., H.D.L., M.J., R.S., L.B., A.A.W.)."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gearoid","family":"O\u2019Neill","sequence":"additional","affiliation":[{"name":"From the Medical College of Virginia, Richmond (K.A.E.); Regional Cardiology Associates, Sacramento, Calif (G.O.); Care Group, LLC, Indianapolis, Ind (E.N.P.); St George\u2019s Hospital Medical School, London, UK (J.A.C); and CV Therapeutics, Palo Alto, Calif (L.M., H.D.L., M.J., R.S., L.B., A.A.W.)."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric N.","family":"Prystowsky","sequence":"additional","affiliation":[{"name":"From the Medical College of Virginia, Richmond (K.A.E.); Regional Cardiology Associates, Sacramento, Calif (G.O.); Care Group, LLC, Indianapolis, Ind (E.N.P.); St George\u2019s Hospital Medical School, London, UK (J.A.C); and CV Therapeutics, Palo Alto, Calif (L.M., H.D.L., M.J., R.S., L.B., A.A.W.)."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John A.","family":"Camm","sequence":"additional","affiliation":[{"name":"From the Medical College of Virginia, Richmond (K.A.E.); Regional Cardiology Associates, Sacramento, Calif (G.O.); Care Group, LLC, Indianapolis, Ind (E.N.P.); St George\u2019s Hospital Medical School, London, UK (J.A.C); and CV Therapeutics, Palo Alto, Calif (L.M., H.D.L., M.J., R.S., L.B., A.A.W.)."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lixin","family":"Meng","sequence":"additional","affiliation":[{"name":"From the Medical College of Virginia, Richmond (K.A.E.); Regional Cardiology Associates, Sacramento, Calif (G.O.); Care Group, LLC, Indianapolis, Ind (E.N.P.); St George\u2019s Hospital Medical School, London, UK (J.A.C); and CV Therapeutics, Palo Alto, Calif (L.M., H.D.L., M.J., R.S., L.B., A.A.W.)."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hsiao Dee","family":"Lieu","sequence":"additional","affiliation":[{"name":"From the Medical College of Virginia, Richmond (K.A.E.); Regional Cardiology Associates, Sacramento, Calif (G.O.); Care Group, LLC, Indianapolis, Ind (E.N.P.); St George\u2019s Hospital Medical School, London, UK (J.A.C); and CV Therapeutics, Palo Alto, Calif (L.M., H.D.L., M.J., R.S., L.B., A.A.W.)."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Markus","family":"Jerling","sequence":"additional","affiliation":[{"name":"From the Medical College of Virginia, Richmond (K.A.E.); Regional Cardiology Associates, Sacramento, Calif (G.O.); Care Group, LLC, Indianapolis, Ind (E.N.P.); St George\u2019s Hospital Medical School, London, UK (J.A.C); and CV Therapeutics, Palo Alto, Calif (L.M., H.D.L., M.J., R.S., L.B., A.A.W.)."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Revati","family":"Shreeniwas","sequence":"additional","affiliation":[{"name":"From the Medical College of Virginia, Richmond (K.A.E.); Regional Cardiology Associates, Sacramento, Calif (G.O.); Care Group, LLC, Indianapolis, Ind (E.N.P.); St George\u2019s Hospital Medical School, London, UK (J.A.C); and CV Therapeutics, Palo Alto, Calif (L.M., H.D.L., M.J., R.S., L.B., A.A.W.)."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luiz","family":"Belardinelli","sequence":"additional","affiliation":[{"name":"From the Medical College of Virginia, Richmond (K.A.E.); Regional Cardiology Associates, Sacramento, Calif (G.O.); Care Group, LLC, Indianapolis, Ind (E.N.P.); St George\u2019s Hospital Medical School, London, UK (J.A.C); and CV Therapeutics, Palo Alto, Calif (L.M., H.D.L., M.J., R.S., L.B., A.A.W.)."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew A.","family":"Wolff","sequence":"additional","affiliation":[{"name":"From the Medical College of Virginia, Richmond (K.A.E.); Regional Cardiology Associates, Sacramento, Calif (G.O.); Care Group, LLC, Indianapolis, Ind (E.N.P.); St George\u2019s Hospital Medical School, London, UK (J.A.C); and CV Therapeutics, Palo Alto, Calif (L.M., H.D.L., M.J., R.S., L.B., A.A.W.)."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"e_1_3_3_1_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(97)00422-1"},{"key":"e_1_3_3_2_2","first-page":"2479","volume":"65","year":"2002","unstructured":"Hebbar AK, Hueston WJ. Management of common arrhythmias, part I: supraventricular arrhythmias. Am Fam Physician. 2002; 65: 2479\u20132486.","journal-title":"Am Fam Physician"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0025-7125(05)70313-8"},{"key":"e_1_3_3_4_2","unstructured":"Miller JM Zipes DP. Management of the patient with cardiac arrhythmias. In: Braunwald E Zipes DP Libby P eds. Heart Disease: A Textbook of Cardiovascular Medicine. 6th ed. Philadelphia Pa: WB Saunders Co; 2001: 700\u2013774."},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/0736-4679(95)02061-6"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0702287"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1177\/107424840100600304"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(03)00987-2"},{"key":"e_1_3_3_9_2","unstructured":"SAS\/STAT User\u2019s Guide Version 8. Cary NC: SAS Institute Inc; 1999."},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1093\/biomet\/75.4.800"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0196-0644(94)70128-8"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0196-0644(05)82650-2"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0196-0644(05)80829-7"},{"key":"e_1_3_3_14_2","first-page":"705","volume":"56","year":"1999","unstructured":"Linden J, Thai T, Figler H, Jin X, Robeva AS. Characterization of human A2B adenosine receptors: radioligand binding, Western blotting, and coupling to Gq in human embryonic kidney 293 cells and HMC-1 mast cells. Mol Pharmacol. 1999; 56: 705\u2013713.","journal-title":"Mol Pharmacol"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1152\/ajplung.00353.2002"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-6147(03)00193-7"},{"key":"e_1_3_3_17_2","unstructured":"Adenocard [prescribing information]. Deerfield Ill: Fujisawa Healthcare Inc; August 2003."},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.2174\/1568026033392246"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1009758501195"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/28.9.1385"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1161\/circ.99.8.1034"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-127-6-199709150-00001"}],"container-title":["Circulation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ahajournals.org\/doi\/full\/10.1161\/CIRCULATIONAHA.104.510982","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T05:00:47Z","timestamp":1715576447000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ahajournals.org\/doi\/10.1161\/CIRCULATIONAHA.104.510982"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,6,21]]},"references-count":22,"journal-issue":{"issue":"24","published-print":{"date-parts":[[2005,6,21]]}},"alternative-id":["10.1161\/CIRCULATIONAHA.104.510982"],"URL":"https:\/\/doi.org\/10.1161\/circulationaha.104.510982","relation":{},"ISSN":["0009-7322","1524-4539"],"issn-type":[{"value":"0009-7322","type":"print"},{"value":"1524-4539","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,6,21]]},"assertion":[{"value":"2005-06-13","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}